45results about How to "Control release time" patented technology

The present invention provides a W / O / W multiple emulsion composition composed of an internal aqueous phase, an oil phase, and an external aqueous phase, the internal aqueous phase containing an ionic physiologically active substance and a physiologically acceptable compound having a molecular weight of 1,000 or less and generating a polyvalent counterion with two or more valencies for the ionic physiologically active substance. The W / O / W emulsion composition of the present invention not only can stably encapsulate a useful substance in its internal aqueous phase at a high encapsulation ratio, but also has high safety.

The invention relates to a multi-stage compound sweetener and a preparation process, belonging to the field of food additives. A multi-stage compound sweetener, the microscopic particles of the powder have an inner and outer double-layer structure, the inner layer is a post-sweet compound layer, the outer layer is a pre-sweet compound layer, and the outer layer of the pre-sweet compound layer The layer is also wrapped with a sweetness inducing layer of natural sweetener ingredients, which is used to present the flavor of natural sweeteners in the first mouthfeel of the food. This technical solution controls the gradient release of artificial sweeteners with different properties and tastes, and mutually eliminates the shortcomings of each sweetener, such as insufficient sweetness, heavy metal taste, and bitterness, so that the overall sweetness is uniform and stable, which is different from natural sweeteners. Close, without bitterness and metallic taste. More importantly, this technical solution proposes to control the release time points of various high-power sweeteners by processing the microstructure of sweeteners, so as to reconcile the appropriate taste, and points out a new direction for the design of compound sweeteners .

The invention provides a recombinant human interferon ε vaginal expansion suppository and a preparation method thereof. The vaginal expansion suppository comprises in parts by weight: 0.1-1.0 parts of recombinant human interferon ε, 10-50 parts of high molecular polymer, 50-200 parts of matrix and 100-500 parts of expansion carrier. The outer layer of the vaginal expansible suppository of the present invention is coated with a high molecular polymer, which effectively controls the release speed and release time of recombinant human interferon ε, so that the drug effect of the vaginal expansive suppository lasts up to 24 hours; The curative effect of recombinant human interferon ε was increased by 3-4 times with the combination of the extracts, the extract of Ziheche, the extract of wild lily and the extract of Scutellaria baicalensis.

The invention provides a recombinant human interferon α1b vaginal expansion suppository and a preparation method thereof. The vaginal expansion suppository comprises, in parts by weight: 0.01-1.0 parts of recombinant human interferon α1b, 10-50 parts of a high molecular polymer, and a matrix 50‑200 parts and swelling carrier 100‑500 parts. The vaginal expansion suppository of the present invention uses recombinant human interferon α1b suitable for Chinese people as the main active ingredient, and has a remarkable curative effect, and its outer layer is coated with a high molecular polymer, which controls the release speed and action time of the active ingredient, reduces the The number of daily administration is reduced, so that the recombinant human interferon α1b can be better absorbed, distributed and metabolized by the human body, with less toxic and side effects.

The invention discloses an oral chronopharmacologic drug delivery mini-pill preparation of propranolol and its salts. The preparation comprises a quick release pill core containing 40-120mg of propranolol and its salts, a slow release layer, an alkaline layer, and a retardation layer, or comprises a slow release pill core containing 40-120mg of propranolol and its salts, the alkaline layer, and the retardation layer, wherein the retardation layer which contains polyacrylic resin III has a weight of 80-200% of the pill core, and the alkaline layer which is a medicinal water-soluble alkaline accessory has a weight of 10-30% of the pill core. The preparation has a characteristic that a medicament which is not immediately released after being orally taken is slowly released from the mini-pill when going through a time lag for 3-4h, and the slow release time can achieve 12-16h, so the daytime blood pressure can be stably controlled, and a purpose that the blood pressure in ten hours or so of early-morning wakefulness and daytime are stably controlled can be achieved.

The invention provides a bonding-type digestive tract support and a production method thereof. The bonding-type digestive tract support comprises a support body, diameters D of two end portions of the support body are 16-20mm, and an adhesive layer is arranged on the outer surface of the support body and composed of, by weight, 85-95 parts of high-molecular resin materials, 2-6 parts of ethylene-ethyl acrylate, 1-5 parts of zinc oxide, 0.5-3 parts of light calcium carbonate, 0.5-2 parts of clinoptilolite powder and 0.3-1 part of wool fat. Introduced bioactive oligopeptide can inhibit staphylococcus and the like to be adhered at infected parts, and the bonding-type digestive tract support has the advantages of conduciveness to rehabilitation of patients and the like.

The invention discloses a method for synthesizing a degradable acid-sensitive polyasparagine copolymer and as a drug and gene co-transporting nanoparticle. The hydrophilic and hydrophobic segments of the present invention are respectively composed of polyaspartic acid grafted with polyethyleneimine and acetalized dextran, and the corresponding molecular weight ratio is 1:1-10. In the preparation method of the present invention, dextran is subjected to an acetalization reaction, and then combined with azide-terminated polyaspartic acid benzyl ester, and polyethylenimine is bonded through the aminolysis reaction of the benzyl ester to prepare a Acetalized Dextran-Polyethyleneimine Grafted Polyaspartic Acid Derivatives with Acid Sensitivity and Degradability. The polymer of the present invention can form nanoparticles with uniform particle size and stability by means of double emulsification, which can be combined with drugs and genes and delivered to tumor cells at the same time, achieving the synergistic effect of tumor chemotherapy and gene therapy. The therapeutic field has broad application prospects.

The invention relates to the field of sustained-release technologies for medicines, in particular to a molecularly imprinted polymer with a controllable sustained-release function. The molecularly imprinted polymer has the advantages that methacrylic acid modified by beta-cyclodextrin is used as a functional monomer, atropine sulfate is used as a template molecule, class specific characteristics of molecularly imprinted polymers are combined with a sustained-release function of the beta-cyclodextrin, and accordingly the molecularly imprinted polymer with the controllable sustained-release function has long-acting medicine release time; the molecularly imprinted polymer with the controllable sustained-release function is customized for medicine template molecules and accordingly is high in selectivity for the released medicine template molecules.